前列地尔联合特利加压素对高龄肝肾综合征患者血栓素B2和6-酮-前列腺素F1α表达的影响

Effects of alprostadil combined with terlipressin on thromboxane B2 and 6-keto-prostaglandin F1αin the elderly patients with hepatorenal syndrome

目的观察前列地尔联合特利加压素对高龄肝肾综合征(HRS)患者血栓素B2(TXB2)和6-酮-前列腺素F1α(6K-PGF1α)表达的影响。方法将28例高龄HRS患者分为HRS非治疗组(12例)和HRS治疗组(16例),另选16例非HRS患者为对照组。对照组及HRS非治疗组给予常规治疗,HRS治疗组在常规治疗基础上,联合使用特利加压素和前列地尔,连续使用7~14d。测定所有研究对象治疗前后血清中TXB2、6KPGF1α的水平。结果治疗前,HRS治疗组和HRS非治疗组患者TXB2水平、TXB2/6K-PGF1α明显高于对照组患者(P<0.05)。HRS治疗组治疗后TXB2水平较治疗前明显降低,6K-PGF1α升高,TXB2/6K-PGF1α显著下降(P<0.05)。治疗后,HRS治疗组TXB2、6K-PGF1α水平与HRS非治疗组比较,差异有统计学意义(P<0.05)。结论前列地尔联合特利加压素能有效改善高龄HRS患者TXB2、6K-PGF1α的水平,从而改善肾功能,值得临床推广使用。

Objective To observe effects of alprostadil combined with terlipressin on thromboxane B2(TXB2)and 6-keto-prostaglandin F1α(6K-PGF1α)in the elderly patients with hepatorenal syndrome(HRS).Methods A total of 28 cases of elderly patients with HRS were divided into HRS non-treatment group(12 cases)and HRS treatment group(16 cases)and 16 cases of patients with non-HRS were selected as control group.The control group and the HRS non-treatment group were treated with conventional treatment.On the basis of conventional treatment,the HRS treatment group was given with terlipressin and alprostadil.The levels of TXB2 and 6K-PGF1αwere measured respectively.Results TXB2 and TXB2/6K-PGF1αlevels in patients of HRS treatment group and HRS non-treatment group were significantly higher than of control group(P<0.05).Compared with those before therapy,TXB2 level and TXB2/6K-PGF1αof patients were significantly declined(P<0.05),6K-PGF1αwas significantly increased in the HRS treatment group after therapy(P<0.05).After therapy,differences of TXB2 and 6K-PGF1αlevels of HRS treatment group and HRS non-treatment group were statistically significant(P<0.05).Conclusion Combination of terlipressin and alprostadil could effectively regulate TXA2 and 6K-PGF1αlevels,improve renal perfusion and recover kidney function,which is worthy of promotion in clinic.